Johnson & Johnson $JNJ is Pinnacle Associates Ltd.'s Largest Position

Key Points

• Pinnacle Associates increased its Johnson & Johnson stake by 0.3% to 1.66 million shares, making J&J its largest portfolio holding at roughly 4.6% of assets and worth about $420.8 million.
• J&J exceeded quarterly earnings and revenue expectations, reporting $2.90 EPS and $25.31 billion in revenue, up 6.6% year over year. The company maintained 2026 EPS guidance of $11.60–$11.75 and declared a $1.34 quarterly dividend, yielding about 2% annually.
• Analysts remain generally positive, with a “Moderate Buy” consensus and an average price target of $268.22, while patent expirations and insider selling remain notable risks for investors.

Pinnacle Associates Ltd. lifted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 0.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,656,912 shares of the company's stock after purchasing an additional 4,246 shares during the quarter. Johnson & Johnson comprises approximately 4.6% of Pinnacle Associates Ltd.'s portfolio, making the stock its largest holding. Pinnacle Associates Ltd. owned approximately 0.07% of Johnson & Johnson worth $420,806,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sterling Group Wealth Management LLC boosted its stake in Johnson & Johnson by 31.5% during the second quarter. Sterling Group Wealth Management LLC now owns 2,907 shares of the company's stock valued at $738,000 after buying an additional 697 shares during the period. PCG Wealth Advisors LLC increased its stake in Johnson & Johnson by 29.3% in the 2nd quarter. PCG Wealth Advisors LLC now owns 1,193 shares of the company's stock worth $303,000 after acquiring an additional 270 shares during the last quarter. First National Bank of Hutchinson raised its holdings in shares of Johnson & Johnson by 11.4% in the 2nd quarter. First National Bank of Hutchinson now owns 11,866 shares of the company's stock valued at $3,014,000 after acquiring an additional 1,217 shares in the last quarter. TSA Wealth Managment LLC boosted its position in shares of Johnson & Johnson by 27.1% during the 2nd quarter. TSA Wealth Managment LLC now owns 1,511 shares of the company's stock valued at $384,000 after acquiring an additional 322 shares during the last quarter. Finally, Bryn Mawr Trust Advisors LLC boosted its position in shares of Johnson & Johnson by 3.1% during the 2nd quarter. Bryn Mawr Trust Advisors LLC now owns 107,673 shares of the company's stock valued at $27,346,000 after acquiring an additional 3,209 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 1.2%

JNJ stock opened at $270.69 on Friday. The company has a market capitalization of $652.34 billion, a PE ratio of 31.37, a price-to-earnings-growth ratio of 2.58 and a beta of 0.24. Johnson & Johnson has a one year low of $173.33 and a one year high of $276.47. The company's 50 day moving average price is $255.08 and its two-hundred day moving average price is $242.72. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. During the same period in the previous year, the business posted $2.77 EPS. The business's quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, analysts predict that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson's payout ratio is currently 62.11%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Elizabeth Forminard sold 15,918 shares of the business's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares of the company's stock, valued at approximately $4,367,458. The trade was a 48.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares of the company's stock, valued at $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 63,972 shares of company stock valued at $16,245,605. Corporate insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on JNJ. Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 3rd. Leerink Partners raised shares of Johnson & Johnson from a "market perform" rating to an "outperform" rating and set a $265.00 price target for the company in a research note on Wednesday, May 13th. Weiss Ratings raised shares of Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, July 24th. Guggenheim raised their price objective on shares of Johnson & Johnson from $270.00 to $287.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Finally, Royal Bank Of Canada lifted their price objective on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an "outperform" rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average price target of $268.22.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted 510(k) clearance for the MONARCH QUEST 3 robotic bronchoscopy update. The system adds artificial-intelligence-powered planning, navigation and imaging capabilities, strengthening J&J’s position in the expanding robotic-assisted medical-procedure market. Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 Update
• Positive Sentiment: The European Commission approved TECVAYLI combined with daratumumab for relapsed or refractory multiple myeloma. The decision was supported by Phase 3 results showing statistically significant progression-free and overall-survival improvements versus standard treatments, potentially expanding sales of J&J’s oncology portfolio. European Commission approves Johnson & Johnson’s TECVAYLI plus daratumumab
• Positive Sentiment: Analysts continue to favor J&J as a dividend-focused healthcare investment, citing its diversified operations and pipeline strength. Recent quarterly results also showed adjusted earnings and revenue ahead of consensus, with revenue up 6.6% year over year and full-year 2026 earnings guidance maintained at $11.60–$11.75 per share. Merck vs. J&J: Which Healthcare Giant Should Investors Choose?
• Neutral Sentiment: J&J’s potential interest in Seaport Therapeutics highlights continued investor focus on neuroscience and business-development opportunities, but no transaction has been announced. Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
• Negative Sentiment: Patent-protection losses remain a longer-term risk for several established drugs, although new medicines and recent approvals could help offset declining legacy-product sales. Johnson & Johnson Just Sent Shareholders an Important Message About Its Future

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source